Hepatitis B virus(HBV)infection increases the risk of liver fibrosis,cirrhosis and hepatocellular carcinoma(HCC)(1).International guidelines recommend antiviral treatment for eligible patients to prevent the developme...Hepatitis B virus(HBV)infection increases the risk of liver fibrosis,cirrhosis and hepatocellular carcinoma(HCC)(1).International guidelines recommend antiviral treatment for eligible patients to prevent the development of HCC and the progression of liver disease.However,there is discrepancy in these guidelines regarding treatment recommendations for patients with compensated cirrhosis and low-level viremia(LLV),defined as serum HBV-DNA level of 20-2,000 IU/mL(2-4).And data on the natural history of untreated compensated cirrhotic patients with LLV is limited.展开更多
基金supported in part by grants from the Chongqing Talents Project(No.cstc2021ycjh-bgzxm0150)the First batch of key Disciplines on Public Health in Chongqing,Health Commission of Chongqing,China+1 种基金the Remarkable Innovation-Clinical Research Project,The Second Affiliated Hospital of Chongqing Medical UniversityScientific and Technological Research Program of Chongqing Municipal Education Commission,The Second Affiliated Hospital of Chongqing Medical University(No.KJZD-K202300404).
文摘Hepatitis B virus(HBV)infection increases the risk of liver fibrosis,cirrhosis and hepatocellular carcinoma(HCC)(1).International guidelines recommend antiviral treatment for eligible patients to prevent the development of HCC and the progression of liver disease.However,there is discrepancy in these guidelines regarding treatment recommendations for patients with compensated cirrhosis and low-level viremia(LLV),defined as serum HBV-DNA level of 20-2,000 IU/mL(2-4).And data on the natural history of untreated compensated cirrhotic patients with LLV is limited.
